^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/11/2020
    Excerpt:
    Indications modified for postremission bevacizumab: It is an option for those with CR/PR after treatment with a bevacizuman-containinhgr regimen, if BRCA1/2 wild type or unknown; it is not recommended for patients with a BRCA1/2 mutation.
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Gynecol Oncol
    Title:

    Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study

    Published date:
    10/01/2020
    Excerpt:
    No evidence of oncological benefit in terms of PFS and OS related to bevacizumab maintenance therapy was found in BRCAmut patients.
    DOI:
    10.1016/j.ygyno.2020.07.022